FGF19 and metabolic dysfunction-associated steatotic liver disease: Considering the beneficial effects of aldafermin against MASLD and its potential as a FGF19 analog to modulate adipose tissue and the liver metabolism, we hypothesized that aldafermin-producing E. coli Nissle 1917 could improve VAT metabolism and modulate VAT-liver crosstalk, therefore alleviating MASLD.